1. A genome-edited N. benthamiana line for industrial-scale production of recombinant glycoproteins with targeted N-glycosylation.
- Author
-
Kogelmann, Benjamin, Melnik, Stanislav, Bogner, Michaela, Kallolimath, Somanath, Stöger, Eva, Sun, Lin, Strasser, Richard, DAoust, Marc-André, Lavoie, Pierre-Olivier, Saxena, Pooja, Gach, Johannes, and Steinkellner, Herta
- Subjects
CRISPR/Cas9 ,N-glycan engineering ,Nicotiana benthamiana ,fucose ,recombinant glycoproteins ,Humans ,Glycosylation ,Recombinant Proteins ,Glycoproteins ,UDP Xylose-Protein Xylosyltransferase ,Polysaccharides ,Plants ,Genetically Modified - Abstract
Control over glycosylation is an important quality parameter in recombinant protein production. Here, we demonstrate the generation of a marker-free genome edited Nicotiana benthamiana N-glycosylation mutant (NbXF-KO) carrying inactivated β1,2-xylosyltransferase and α1,3-fucosyltransferase genes. The knockout of seven genes and their stable inheritance was confirmed by DNA sequencing. Mass spectrometric analyses showed the synthesis of N-glycans devoid of plant-specific β1,2-xylose and core α 1,3-fucose on endogenous proteins and a series of recombinantly expressed glycoproteins with different complexities. Further transient glycan engineering towards more diverse human-type N-glycans resulted in the production of recombinant proteins decorated with β1,4-galactosylated and α2,6-sialylated structures, respectively. Notably, a monoclonal antibody expressed in the NbXF-KO displayed glycosylation-dependent activities. Collectively, the engineered plants grow normally and are well suited for upscaling, thereby meeting industrial and regulatory requirements for the production of high-quality therapeutic proteins.
- Published
- 2024